Biosergen

Biosergen EBIT Margin

The EBIT Margin (Operating Margin) of Biosergen (BIOSGN.ST) as of Oct 18, 2026 is -397.50 %. In the previous year, EBIT Margin (Operating Margin) was -140.48 % — a change of 182.96% (lower).

EBIT Margin

-397.50 %

YoY

182.96%

Last updated:

EBIT Margin (Operating Margin) of Biosergen is 2021 -397.50 % . EBIT Margin (Operating Margin) of Biosergen was 2020 -140.48 % . It decreases by 182.96% lower compared to the previous year.

Biosergen's operating (EBIT) margin stands at -397.5%, down from -392.4% several years earlier.

The Biosergen EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-392.39 SEK
Jan 1, 2020
-140.48 SEK
Jan 1, 2021
-397.50 SEK
The Biosergen EBIT Margin history
YEAREBIT MarginYoY
-397.50 %+182.96%
-140.48 %-64.20%
-392.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Biosergen Stock analysis

What does Biosergen do? Biosergen AB is a biopharmaceutical company headquartered in Solna, Sweden. The company went public on June 24, 2021, with its ticker symbol BIOSGN.ST and ISIN SE0026821852. Biosergen AB conducts biopharmaceutical research and development through its subsidiary Biosergen AS, utilizing laboratory facilities in Trondheim, Norway, and other global locations. The company is focused on developing BSG005, an antifungal drug that has shown safety and potency benefits compared to existing treatments. BSG005 is designed to address invasive fungal infections affecting immune-compromised patients, including those with AIDS, cancer, or who have undergone transplants. At equivalent doses, BSG005 has demonstrated a three- to fourfold higher potency against targeted fungal strains than current standard treatments, while avoiding the kidney toxicity associated with other drugs in its class. Biosergen AB operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is biosergen.net, providing further information about its research and development activities. The firm's primary focus remains on advancing BSG005 through clinical development, targeting a significant unmet medical need in the treatment of fungal infections among vulnerable patient populations. Biosergen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biosergen stock

EBIT Margin (Operating Margin) of Biosergen is -397.50 % in 2021.

EBIT Margin (Operating Margin) of Biosergen changed from -140.48 % to -397.50 %, representing a 182.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Biosergen since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Biosergen with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Biosergen

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Biosergen